Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH

A Phase 2, Placebo-Controlled, Double-Blind, Randomized Withdrawal Study to Determine the Safety and Efficacy of Oral SDX in Patients With Idiopathic Hypersomnia (IH)

This is a study of the safety, efficacy and pharmacokinetics (PK) of Serdexmethylphenidate (SDX) compared to placebo in subjects with Idiopathic Hypersomnia (IH).

Study Overview

• Status: Active, not recruiting
• Conditions: Idiopathic Hypersomnia
• Intervention / Treatment: Drug: Serdexmethylphenidate; Other: Placebo

Detailed Description

SDX is a prodrug of dexmethylphenidate (d-MPH). SDX behaves as a prototypical prodrug that is devoid of pharmacological effects until metabolized to active d-MPH. Central nervous system (CNS) stimulants, including d-MPH products, are being used off-label by patients with IH. The potential advantage of SDX-derived d-MPH is its unique PK profile with rising d-MPH plasma concentrations at approximately 3 hours postdose followed by a broad peak from approximately 8 to 12 hours postdose (without sharp exposure spikes), and a gradual decline after the peak.

The optimal dose of SDX will be determined for each participant by titration based on individual tolerability and response during the 5-week SDX-only Open-Label Titration period (OLTP), after which 2/3 of the participants will continue to receive SDX and 1/3 of the participants will receive placebo (withdrawal design) in the 2-week Double-Blind Withdrawal Period (DBWP).

The study will evaluate safety (primary endpoint), efficacy and PK in patients with IH after daily oral administration of SDX either once per day in the evening (qd pm) or twice per day (morning and evening: bid). The study is expected to inform about the optimal SDX dose range and the best dose regimen (nighttime dosing or twice-per-day) for further studies in patients with IH and narcolepsy. The evening dosing regimen (just before bedtime) is of interest since there is little or no exposure to d-MPH for the first several hours post-dose and the mean peak d-MPH concentration occurs at 10-12 hours post-dose (ie, in the morning after a nighttime dose).

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Medical Affairs; Phone Number: 1-888-289-5607; Email: medicalaffairs@zevra.com

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35201
      • Sleep Disorders Center of Alabama
    • Daphne, Alabama, United States, 36526
      • AMR Daphne
    • Guntersville, Alabama, United States, 35976
      • Lakeview Clinical Research
  • California
    • Huntington Beach, California, United States, 92647
      • SoCal Clinical Research
    • Redwood City, California, United States, 94063
      • Stanford University
    • San Ramon, California, United States, 94583
      • Sleep Medicine Specialists of California
    • Santa Ana, California, United States, 92701
      • SDS Clinical Trials, Inc
  • Colorado
    • Colorado Springs, Colorado, United States, 80903
      • Delta Waves, Inc.
  • Florida
    • Clearwater, Florida, United States, 33755
      • Saint Francis Sleep Allergy and Lung Institute LLC
    • Hialeah, Florida, United States, 33010
      • New Generation of Medical Trials
    • Miami, Florida, United States, 33144
      • Clinical Trial Services, Corp
    • Miami, Florida, United States, 33122
      • Angels Clinical Research
    • Miami, Florida, United States, 33130
      • Ivetmar Medical Group
    • Miami, Florida, United States, 33130
      • Somnology Research Associates
    • Saint Petersburg, Florida, United States, 33707
      • Pasadena Center for Medical Research
    • Winter Park, Florida, United States, 32789
      • Clinical Site Partners, LLC - Winter Park
  • Georgia
    • Atlanta, Georgia, United States, 30303
      • Global Research Associates
    • Atlanta, Georgia, United States, 30303
      • Neurotrials Research, Inc
    • Stockbridge, Georgia, United States, 30281
      • Clinical Research Institute - Stockbridge
  • Kansas
    • Kansas City, Kansas, United States, 64106
      • The University of Kansas Medical Center Research Institution Inc.
  • Maryland
    • Bethesda, Maryland, United States, 20817
      • Mid-Atlantic Epilepsy and Sleep Center - Bethesda
  • Massachusetts
    • Newton, Massachusetts, United States, 02459
      • Neurocare, Inc.
  • Michigan
    • Kalamazoo, Michigan, United States, 49007
      • Western Michigan University Homer Stryker Md School of Medicine
    • Novi, Michigan, United States, 48375
      • Henry Ford Health - Columbus
    • Sterling Heights, Michigan, United States, 48313
      • Clinical Neurophysiology Services PC
  • Missouri
    • Columbia, Missouri, United States, 65211
      • University of Missouri School of Medicine
    • Saint Louis, Missouri, United States, 63123
      • Clayton Sleep Institute, LLC
  • Nebraska
    • La Vista, Nebraska, United States, 68128
      • Barrett Clinic
  • New Jersey
    • Lawrence Township, New Jersey, United States, 08648
      • Global Medical Institutes LLC- Princeton Medical Institute
  • North Carolina
    • Gastonia, North Carolina, United States, 28052
      • Clinical Research of Gastonia (CRG)
  • Ohio
    • Cincinnati, Ohio, United States, 45202
      • Intrepid Research
    • Dublin, Ohio, United States, 43017
      • Ohio Sleep Medicine Institute
  • Pennsylvania
    • Malvern, Pennsylvania, United States, 19355
      • Brian Abaluck, LLC
    • Philadelphia, Pennsylvania, United States, 19107
      • Thomas Jefferson University
  • South Carolina
    • Charleston, South Carolina, United States, 29401
      • Medical University Of South Carolina (MUSC) - Institute Of Psychiatry (IOP)
    • Columbia, South Carolina, United States, 29201
      • Bogan Sleep Consultants
  • Texas
    • Austin, Texas, United States, 78701
      • FutureSearch Trials of Neurology
    • Fort Worth, Texas, United States, 76244
      • Dfw Clinical Research Associates
    • Houston, Texas, United States, 77002
      • Houston Clinical Research Associates
    • San Antonio, Texas, United States, 78205
      • Sleep Therapy & Research Center
  • Virginia
    • Williamsburg, Virginia, United States, 23185
      • TPMG Clinical Research - Williamsburg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. At least 18 years of age at the time of consent
2. Body Mass Index (BMI) ≤35 kg/m2
3. Documented primary diagnosis of IH according to the International Classification of Sleep Disorders (ICSD-3) criteria
4. At the Screening Visit and Baseline Visit (start of OLTP), Epworth Sleepiness Scale (ESS) scores ≥11
5. Average nightly Total Sleep Time (TST) of ≥7 hours, per subject history and confirmed during screening.
6. Subject must be in general good health defined as the absence of any clinically relevant abnormalities as determined by the Investigator based on physical and neurological examinations, vital signs, ECGs, medical history, and clinical laboratory values (hematology, chemistry, and urinalysis) at Screening.
7. If currently treated with nicotine replacement therapy, must have been taking the same regimen and dose for at least 2 months prior to screening and must agree to take the same dose during the study.
8. Have used a medically acceptable method of contraception for at least 2 months prior to the first dose of study drug and consent to use a medically acceptable method of contraception from the first dose of study drug, throughout the entire study period, and for 90 days after the last dose of study drug.

Exclusion Criteria

1. Hypersomnia due to another medical, behavioral, or psychiatric disorder condition (eg, narcolepsy, depression disorders, multiple sclerosis, Parkinson's disease, stroke).
2. Clinically significant sleep-related breathing disorders, including sleep apnea, treatment with Continuous Positive Airway Pressure (CPAP) therapy, Obstructive Apnea Hypopnea Index (AHI) >15 episodes per hour, or hypoventilation.
3. Clinically significant parasomnias (eg, sleep walking, rapid eye movement [REM] sleep behavior disorder, etc).
4. Periodic Limb Movement Disorder (PLMD) Arousal Index (PLMA-I) >15 during Screening PSG, a historical diagnosis of PLMD (last 10 years), or a PLMD diagnosis older than 10 years with current (last 60 days) treatment or symptoms of rhythmic movements involving one or both legs during sleep.
5. Occupation requiring nighttime shift work or variable shift work with early work start times (before 6 AM), if this occurs more than once per week.
6. Planned travel during the study that includes more than 3 time zones, or planned travel that includes 3 time zones on more than 2 occasions during the study.
7. Going to sleep for the night later than 1 AM at a frequency of more than once per week.
8. Current or past (within 1 year) major depressive episode according to DSM-5 criteria.
9. Any history of attempted suicide (lifetime) or clinically significant suicidal ideation, in the opinion of the Investigator, based on the C-SSRS assessment at Screening.
10. Any clinically significant unstable medical abnormality, chronic disease (eg, asthma or diabetes), or a history of a clinically significant abnormality of the cardiovascular, central nervous system,
11. Any of the following out-of-range vital signs at Screening: systolic blood pressure outside 90-145 mmHg; diastolic blood pressure outside 50-90 mmHg; resting heart rate outside 40-100 beats per minute.

12. History or presence of abnormal ECGs, which in the Investigator's opinion is clinically significant, including the following:

    1. ECG findings of ischemia or infarct
    2. Complete bundle branch blocks
    3. Symptomatic arrhythmias as ventricular arrhythmias (non- sustained ventricular tachycardia (VT), multifocal or frequent premature ventricular contractions), bundle branch block, axis deviation, or abnormal or any predominantly non-sinus- conducted rhythm.
    4. QTcF >450 msec for males or >470 msec for females, on Screening ECG.
    5. PR interval outside the range of 120 to 220 msec on Screening ECG
13. Estimated glomerular filtration rate (GFR) at Screening <60 mL/min/1.73 m2.
14. Malignant neoplastic disease requiring therapy within 2 years prior to Screening or during the study, or clinically relevant as judged by the Investigator.
15. Uncontrolled thyroid disorder as evidenced by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥1.25 x the upper limit of normal (ULN) for the reference laboratory at Screening.
16. Laboratory value for aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x upper limits of normal (ULN).
17. Excessive caffeine use during the 10 days prior to first dose of study drug or anticipated excessive use defined as >600 mg/day of caffeine during the treatment periods of the study.
18. Treatment or planned treatment with prohibited medications (including medications that may affect daytime sleepiness and nighttime sleep) or unwilling to refrain from any prohibited medications. Treatment must have been discontinued 14 days or 5 half-lives, whichever is longer, prior to the first dose of study medication (and at least 30 days for sedating antidepressants; at least 14 days for CNS stimulants).
19. Current or past (within 12 months prior to Screening) substance use disorder (including alcohol and psychoactive cannabinoids) according to DSM-5 criteria; current or past history of substance abuse treatment (including alcohol), or unwilling to refrain from substance use (including alcohol) during the study.
20. Nicotine dependence that has an effect on sleep (eg, a subject who routinely awakens at night to smoke).
21. Evidence of substance or alcohol use or has a positive urine or breath alcohol or positive urine drug screen at Screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Experimental: SDX; SDX capsules at the optimized daily dose, once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)	Drug: Serdexmethylphenidate; Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.; Other Names: SDX
Placebo Comparator: Active Comparator; Placebo capsules once in the evening daily (qd pm) or twice per day (bid), for 2 weeks (DBWP)	Drug: Serdexmethylphenidate; Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.; Other Names: SDX; Other: Placebo; Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety parameters - TEAEs	Type and frequency of Treatment-Emergent Adverse Events	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Safety parameter - Heart Rate	Change from baseline in heart rate (beats/minute).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Safety parameter - Blood Pressure	Change from baseline in blood pressure (mmHg).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Safety parameter - Laboratory Tests	Clinical significant change from baseline in clinical laboratory tests.	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Safety parameter - ECG	Clinical significant change from baseline in electrocardiogram (ECG).	Time Frame: Start of OLTP to end of DBWP (7 weeks)
Safety parameter - PSQI	Change from baseline in Pittsburg Sleep Quality Index Question #6. Sleep quality score ranging from very good (0) to very bad (4).	Time Frame: Start of OLTP to end of DBWP (7 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change from baseline in Epworth Sleepiness Scale (ESS) score	Scores level of daytime sleepiness ranging from 0 to 24, with a higher score indicating worsened sleepiness	Start to end of DBWP (2 weeks)
Change from baseline in Brain Fog score	Queries for frequency, severity, and symptoms of cognitive impairment in the last week.	Time Frame: Start to end of DBWP (2 weeks)
Percentage of participants with increase (worsening) of 2 points or more from baseline in the Clinical Global Impression of Severity (CGI-S)	Clinician-reported level of illness.	Start to end of DBWP (2 weeks)
Percentage of participants with increase (worsening) of 2 points or more baseline in the Patient Global Impression of Severity (PGI-S).	Patient-reported level of illness.	Start to end of DBWP (2 weeks)
Change from baseline in Total Score of the Idiopathic Hypersomnia Severity Hypersomnia Scale (IHSS)	Patient-reported questionnaire assessing the severity of excessive sleepiness, prolonged sleep duration, cognitive impairment and sleep inertia. The total score ranges from 0 to 50, with higher scores indicating more severe symptoms.	Start to end of DBWP (2 weeks)
Change from baseline in Modified Karolinska Sleepiness Scale in the morning and late afternoon.	Patient-reported at-the-moment sleepiness, ranging from 1 (extremely alert) to 10 (extremely sleepy, can't keep awake).	Start to end of DBWP (2 weeks)
Change from baseline in Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) total scores for depression, fatigue, and social functioning.	Queries functioning and well-being in the last week.	Start to end of DBWP (2 weeks)
Change from baseline in the Patient-Reported Wakefulness Questionnaire (ZOGIM-A) total scores.	Queries alertness over the course of the day.	Start to end of DBWP (2 weeks)
Change from baseline in the Sleep Inertia Visual Analog Scale (SIVAS) score.	Patient-reported measure of the difficulty of waking up in the morning, ranging from 0 (very easy) to 100 (very difficult)	Start to end of DBWP (2 weeks)

Collaborators and Investigators

• Sponsor: Zevra Therapeutics
• Collaborators: Rho, Inc.
• Investigators: Principal Investigator: Christopher Drake, PhD, Investigator

Study record dates

Study Major Dates

• Study Start (Actual): December 28, 2022
• Primary Completion (Estimated): June 30, 2024
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: December 19, 2022
• First Submitted That Met QC Criteria: December 29, 2022
• First Posted (Actual): December 30, 2022

Study Record Updates

• Last Update Posted (Actual): January 9, 2024
• Last Update Submitted That Met QC Criteria: January 8, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Nervous System Diseases; Sleep Disorders; Mental Disorders; Disorders of Excessive Somnolence; Sleep Wake Disorders; Intrinsic Dyssomnias
• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Disorders of Excessive Somnolence; Idiopathic Hypersomnia
• Other Study ID Numbers: KP1077.D01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No